RightsIssue Participation Supports Clinical-Enabling Studies
Filed with ASX ·
6ix hasn’t read this filing yet.
Amplia Therapeutics Ltd. on 6ix
Earlier from Amplia Therapeutics
- Amplia Therapeutics Reports Lead Candidate Preclinical Data
- Rights Issue Prospectus
- Dr John Lambert appointed as new CEO
- Capital Raising for Clinical-Enabling Studies
- Preliminary Final Report - Year Ended 31 March 2019
Later from Amplia Therapeutics
- Appendix 4C - Quarterly Cash Flow Report - June 2019 Qtr
- App 4C - Sep 2019 Qtr Cash Flows Statement
- App 4D - Financial Report Half Year Ended 30 Sep 2019
- Amplia Therapeutics Undertakes Placement
- Appendix 4C Cash Flow - Dec 2019 Qtr
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics